Abstract
Objective:The aim of the COVER Study is to identify global outcomes and decision making for vascular procedures during the pandemic.Background Data:During its initial peak, there were many reports of delays to vital surgery and the release of several guidelines advising later thresholds for vascular surgical intervention for key conditions.Methods:An international multi-center observational study of outcomes after open and endovascular interventions.Results:In an analysis of 1103 vascular intervention (57 centers in 19 countries), 71.6% were elective or scheduled procedures. Mean age was 67 ± 14 years (75.6% male). Suspected or confirmed COVID-19 infection was documented in 4.0%. Overall, in-hospital mortality was 11.0% [aortic interventions mortality 15.2% (23/151), amputations 12.1% (28/232), carotid interventions 10.7% (11/103), lower limb revascularisations 9.8% (51/521)]. Chronic obstructive pulmonary disease [odds ratio (OR) 2.02, 95% confidence interval (CI) 1.30–3.15] and active lower respiratory tract infection due to any cause (OR 24.94, 95% CI 12.57–241.70) ware associated with mortality, whereas elective or scheduled cases were lower risk (OR 0.4, 95% CI 0.22–0.73 and 0.60, 95% CI 0.45–0.98, respectively. After adjustment, antiplatelet (OR 0.503, 95% CI: 0.273–0.928) and oral anticoagulation (OR 0.411, 95% CI: 0.205–0.824) were linked to reduced risk of in-hospital mortality.Conclusions:Mortality after vascular interventions during this period was unexpectedly high. Suspected or confirmed COVID-19 cases were uncommon. Therefore an alternative cause, for example, recommendations for delayed surgery, should be considered. The vascular community must anticipate longer term implications for survival.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have